RxDoctor Payments Data

Amanda Rosswog, PA

Physician Assistant · Butler, PANPI 1881354769

Payments from drug & device makers

$1,222in general payments, 2019–2025

Across 76 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$526
  • Medtronic$213
  • Pfizer$207
  • AbbVie$162
  • Palette Life Sciences, Inc.$36
  • Olympus America Inc.$25
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$1,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,222 in reported general payments places this provider in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,244
Medicare patients
267
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron213$133,308
Mirabegron ErMirabegron42$22,518
GemtesaVibegron31$21,874
Tamsulosin Hcl482$9,604
Solifenacin Succinate275$7,358
PremarinEstrogens, Conjugated16$6,645
Potassium Citrate ErPotassium Citrate55$6,428
Trimethoprim54$2,441
Finasteride135$1,591
Methenamine Hippurate14$1,235
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst68$739
Oxybutynin Chloride57$719
Alfuzosin Hcl ErAlfuzosin Hcl19$506
Dutasteride20$454
Cephalexin65$431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$526$21,87431 claims
PfizerPremarin$207$6,64516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →